SNNA News and Press, Sienna Biopharmaceuticals Inc. From 06/10/19

-- Phase 2b Trial Results Demonstrated SNA-120 Had Significant Impact on Psoriasis and Was Well-Tolerated WESTLAKE VILLAGE, Calif., June 10, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA), a clinical-stage biopharmaceutical company, today announced that the r...

WESTLAKE VILLAGE, Calif., May 21, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA), a clinical-stage biopharmaceutical company, today announced that Paul F. Lizzul, M.D., Ph.D., Chief Medical Officer, and Silvio Traversa, B.Sc., Ph.D., Chief Scientific Officer, are s...

-- Biopsy data support strong clinical effect observed in Phase 2 trials with SNA-120  -- Following Positive End-of-Phase 2 meeting with FDA, Sienna continues toward enrolling first patient in Phase 3 program in second half of 2019 WESTLAKE VILLAGE, Calif., May 14, 2019 (GLOB...

WESTLAKE VILLAGE, Calif., May 09, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA) today announced that Frederick C. Beddingfield III, M.D., Ph.D., President and Chief Executive Officer of Sienna, is scheduled to present at the Bank of America Merrill Lynch Health ...

Sienna Biopharmaceuticals (NASDAQ: SNNA ): Q1 GAAP EPS of -$0.67 misses by $0.17 . More news on: Sienna Biopharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

-- Company Completed Positive End-of-Phase 2 Meeting with FDA for SNA-120 in Psoriasis WESTLAKE VILLAGE, Calif., May 08, 2019 (GLOBE NEWSWIRE) --   Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA) today reported the Company’s financial results for the first quarter of 2019. ...

People who LIKE movies have a favorite. People who LOVE movies couldn't possibly choose .” ― Nicole Yatsonsky Today we look at a small developmental firm with multiple shots on goal but that has largely destroyed shareholder value since coming public. The shares seem to have...

-- John W. Smither Departing for Personal Reasons WESTLAKE VILLAGE, Calif., March 21, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA), a clinical-stage biopharmaceutical company, today announced the promotion of Alexander Azoy to Chief Financial Officer (CFO)....

Sienna Biopharmaceuticals (NASDAQ: SNNA ): Q4 GAAP EPS of -$0.93. More news on: Sienna Biopharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

WESTLAKE VILLAGE, Calif., March 14, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA), a clinical-stage biopharmaceutical company, today reported the Company’s financial results for the fourth quarter and full year of 2018. “We are pleased to report...